Real world clinical outcomes of treatment of cannabis-induced psychosis and prevalence of cannabis-related primary psychosis: a retrospective study.
Cannabis
Cannabis-induced psychosis
Cannabis-related primary psychosis
Treatment of cannabis-induced psychosis
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
28
02
2024
accepted:
11
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Current treatment of cannabis-induced psychosis (CIP) focus on the presenting symptoms of individual patient. Therefore, the objective of this study was to investigate the efficacy of pharmacological treatment for CIP in a retrospective manner. A retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. Patients aged more than 12 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP, had recorded of cannabis use in medical chart, and had positive urine test of cannabis on the first day of admission from October 2013 to September 2019 were enrolled. The primary outcome was the efficacy of pharmacological treatment of CIP. Brief Psychotic Rating Scale (BPRS) on the first day and weekly after receiving treatment were used to assess the primary outcome. Four hundred and three medical charts with diagnosis of CIP were enrolled into the study and only 317 charts were analyzed. Most of them were male with an average aged of 21.0 (19.0-24.0) years old. All of them used smoked cannabis from dried leaves and flowers of cannabis plant. The presented symptoms on admission were psychosis, mood symptoms, sleep problems, weight loss, and cognitive problems (100%, 64%, 61%, 11%, and 7%, respectively). Baseline BPRS score of the first day of admission was 55.2 ± 9.6. Majority of patients received antipsychotic (98.7%) followed by the combination of antipsychotics with benzodiazepines (34.5.%), antipsychotics with antidepressants (14.4%) and antipsychotics treatment with antidepressants and benzodiazepines (25.9%). Only few patients received antipsychotic monotherapy (17.9%). Risperidone was the most frequently prescribed antipsychotics (83.6%). Mean equivalence dose of risperidone was 8.0 ± 5.9 mg/day. The average hospital length of stay was 28 days (range 22-31). BPRS at 22 days significantly improved compared to the first day of admission (p < 0.001). Schizophrenia was diagnosed in 7% at 1.3 years of follow up. Antipsychotics was still a key psychotropic drug for treatment of CIP. The symptoms were decreased rapidly and sustained among the treatment period. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychosis. ClinicalTrials.gov ID: NCT04945031 (Registration Date: 30 June, 2021).
Sections du résumé
BACKGROUND
BACKGROUND
Current treatment of cannabis-induced psychosis (CIP) focus on the presenting symptoms of individual patient. Therefore, the objective of this study was to investigate the efficacy of pharmacological treatment for CIP in a retrospective manner.
METHODS
METHODS
A retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. Patients aged more than 12 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP, had recorded of cannabis use in medical chart, and had positive urine test of cannabis on the first day of admission from October 2013 to September 2019 were enrolled. The primary outcome was the efficacy of pharmacological treatment of CIP. Brief Psychotic Rating Scale (BPRS) on the first day and weekly after receiving treatment were used to assess the primary outcome.
RESULTS
RESULTS
Four hundred and three medical charts with diagnosis of CIP were enrolled into the study and only 317 charts were analyzed. Most of them were male with an average aged of 21.0 (19.0-24.0) years old. All of them used smoked cannabis from dried leaves and flowers of cannabis plant. The presented symptoms on admission were psychosis, mood symptoms, sleep problems, weight loss, and cognitive problems (100%, 64%, 61%, 11%, and 7%, respectively). Baseline BPRS score of the first day of admission was 55.2 ± 9.6. Majority of patients received antipsychotic (98.7%) followed by the combination of antipsychotics with benzodiazepines (34.5.%), antipsychotics with antidepressants (14.4%) and antipsychotics treatment with antidepressants and benzodiazepines (25.9%). Only few patients received antipsychotic monotherapy (17.9%). Risperidone was the most frequently prescribed antipsychotics (83.6%). Mean equivalence dose of risperidone was 8.0 ± 5.9 mg/day. The average hospital length of stay was 28 days (range 22-31). BPRS at 22 days significantly improved compared to the first day of admission (p < 0.001). Schizophrenia was diagnosed in 7% at 1.3 years of follow up.
CONCLUSION
CONCLUSIONS
Antipsychotics was still a key psychotropic drug for treatment of CIP. The symptoms were decreased rapidly and sustained among the treatment period. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychosis.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov ID: NCT04945031 (Registration Date: 30 June, 2021).
Identifiants
pubmed: 39334053
doi: 10.1186/s12888-024-06075-6
pii: 10.1186/s12888-024-06075-6
doi:
Substances chimiques
Antipsychotic Agents
0
Banques de données
ClinicalTrials.gov
['NCT04945031']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
626Informations de copyright
© 2024. The Author(s).
Références
Pisanu A, Acquas E, Fenu S, Di Chiara G. Modulation of Delta (9)-THC-induced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors. Neuropharmacology. 2006;50(6):661–70.
doi: 10.1016/j.neuropharm.2005.11.023
pubmed: 16427098
Andreasson SAP, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longtitudinal study of Swedish conscripts. Lancet. 1987;2:1493–6.
Crean RD, Crane NA, Mason BJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1–8.
doi: 10.1097/ADM.0b013e31820c23fa
pmcid: 3037578
pubmed: 21321675
Ranganathan M, D’Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006;188(4):425–44.
doi: 10.1007/s00213-006-0508-y
pubmed: 17019571
Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427–36.
doi: 10.1016/S2215-0366(19)30048-3
pmcid: 7646282
pubmed: 30902669
Treatment PMNIDA. Number and percent of patient 2019. http://www.pmnidat.go.th/thai/index.php?option=com_content&task=view&id=3274&Itemid=53 . Accessed 18 Jan 2020.
Berk M, Brook S, Trandafir AI. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999;14(3):177–80.
doi: 10.1097/00004850-199905030-00005
pubmed: 10435771
Berk S, Brook F, Nur M. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double blind randomized controlled trial. Int J Psychiatry Clin Pract. 2000;4(2):139–42.
doi: 10.3109/13651500009177999
Bell MMR, Beam-goulet J, Lysaker P, Cicchetti D. The positive and negative syndrome scale and the brief Psychiatric Rating Scale. J Nerv Ment Dis. 1992;180:723–8.
doi: 10.1097/00005053-199211000-00007
pubmed: 1431824
Overall JEGD. The brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799–812.
doi: 10.2466/pr0.1962.10.3.799
Sommano SR, Tangpao T, Pankasemsuk T, Ponpanumas V, Phimolsiripol Y, Rachtanapun P, et al. Growing ganja permission: a real gate-way for Thailand’s promising industrial crop? J Cannabis Res. 2022;4(1):10.
doi: 10.1186/s42238-022-00121-4
pmcid: 8898406
pubmed: 35249552
Compton DRJM, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther. 1992;260:201–9.
pubmed: 1309872
Hsieh JH, Stein DJ, Howells FM. The neurobiology of methamphetamine induced psychosis. Front Hum Neurosci. 2014;8:537.
doi: 10.3389/fnhum.2014.00537
pmcid: 4105632
pubmed: 25100979
Gazette TR, editor. List of narcotic drug type 5. In: Health Mo, editor. Bangkok 14 December B.E. 2563 (2020) Thai government; 2020. pp. 33–4.
PMNIDAT. Number an percent of inpatients 2023. http://www.pmnidat.go.th/thai/index.php?option=com_content&task=view&id=4597&Itemid=53 . Accessed 6 Feb 2024.
Morales-Munoz I, Jurado-Barba R, Ponce G, Martinez-Gras I, Jimenez-Arriero MA, Moratti S, et al. Characterizing cannabis-induced psychosis: a study with prepulse inhibition of the startle reflex. Psychiatry Res. 2014;220(1–2):535–40.
doi: 10.1016/j.psychres.2014.08.010
pubmed: 25175914
Nunez LAGM. Cannabis-induced psychosis: a cross-sectional comparison with acute schizhophrenia. Acta Psychiatr Scand. 2002;105:173–8.
doi: 10.1034/j.1600-0447.2002.1o079.x
pubmed: 11939970
Frolli A, Ricci MC, Cavallaro A, Lombardi A, Bosco A, Di Carmine F, et al. Cognitive Development and Cannabis Use in adolescents. Behav Sci (Basel). 2021;11(3):37.
doi: 10.3390/bs11030037
pubmed: 33802852
Jacobus JTS. Effects of Cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13):2186–93.
doi: 10.2174/13816128113199990426
pmcid: 3930618
pubmed: 23829363
Ho B-C, Barry AB, Koeppel JA, Macleod J, Boyd A, David A, et al. Recreational Marijuana Use, adolescent Cognitive Development, and Schizophrenia susceptibility. Biol Psychiatry Glob Open Sci. 2022;3(2):222–32.
doi: 10.1016/j.bpsgos.2022.01.008
pmcid: 10140454
pubmed: 37124347
Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, et al. Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open. 2016;6(3):e009888.
doi: 10.1136/bmjopen-2015-009888
pmcid: 4785290
pubmed: 26940105
Mizrahi R, Watts JJ, Tseng KY. Mechanisms contributing to cognitive deficits in cannabis users. Neuropharmacology. 2017;124:84–8.
doi: 10.1016/j.neuropharm.2017.04.018
pmcid: 5540783
pubmed: 28414051
Schooler N, Rabinowitz J, Davidson M, Harvey PD, Kopala L, McGorry PD, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947–53.
doi: 10.1176/appi.ajp.162.5.947
pubmed: 15863797
Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Delta (9)-tetrahydrocannabinol on the dopamine system. Nature. 2016;539(7629):369–77.
doi: 10.1038/nature20153
pmcid: 5123717
pubmed: 27853201
Rozin E, Vanaharam V, D’Mello D, Palazzolo S, Adams C. A retrospective study of the role of long-acting injectable antipsychotics in preventing rehospitalization in early psychosis with cannabis use. Addict Behav Rep. 2019;10:100221.
pmcid: 6888881
pubmed: 31828200
Andrew J. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178:116–22.
doi: 10.1192/bjp.178.2.116
Imade AGTEJ. A retrospective study of symptom patterns of cannabis-induced psychosis. Acta Psychiatr Scand. 1991;83:134–6.
doi: 10.1111/j.1600-0447.1991.tb07378.x
pubmed: 2017910
Murrie B, Lappin J, Large M, Sara G. Transition of Substance-Induced, brief, and atypical psychoses to Schizophrenia: a systematic review and Meta-analysis. Schizophr Bull. 2020;46(3):505–16.
doi: 10.1093/schbul/sbz102
pubmed: 31618428
Paes-Colli Y, Trindade PMP, Vitorino LC, Piscitelli F, Iannotti FA, Campos RMP, et al. Activation of cannabinoid type 1 receptor (CB1) modulates oligodendroglial process branching complexity in rat hippocampal cultures stimulated by olfactory ensheathing glia-conditioned medium. Front Cell Neurosci. 2023;17:1134130.
doi: 10.3389/fncel.2023.1134130
pmcid: 10150319
pubmed: 37138770
DeLisi LE. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry. 2008;21(2):140–50.
doi: 10.1097/YCO.0b013e3282f51266
pmcid: 4337025
pubmed: 18332661
Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol. 2014;4:169.
doi: 10.3389/fphar.2013.00169
pmcid: 3877778
pubmed: 24427139
Caballero A, Tseng KY. Association of Cannabis Use during adolescence, prefrontal CB1 receptor signaling, and Schizophrenia. Front Pharmacol. 2012;3:101.
doi: 10.3389/fphar.2012.00101
pmcid: 3361072
pubmed: 22654759